# Amgen: Who Leads Obesity And IMIDs Allka Research 3.35K Followers Comment (1) Summary Amgen Inc.

*business · news · 2026-04-09 · Seeking Alpha*

## Key points

- Amgen is actively seeking to enter the GLP-1 obesity drug market dominated by Eli Lilly.
- Both Amgen and Eli Lilly have notable gaps in their drug portfolios compared to each other.
- Amgen and Eli Lilly are leading competitors in the immune-mediated inflammatory diseases treatment sector.
- The article provides a comparative long-term investment outlook for Amgen versus Eli Lilly.

**Companies:** Eli Lilly and Company, Amgen Inc.

[Read the full story on Seeking Alpha](https://seekingalpha.com/article/4889500-eli-lilly-vs-amgen-who-leads-obesity-and-imids)

---

Canonical: https://newsio.io/n/cab6f769-8cb9-482f-ad6d-299f73fb862c/amgen-who-leads-obesity-and-imids-allka-research-3-35k-followers-comment-1-summa
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works